Summary
We studied the lymphokine-activated killer (LAK) activity in splenocytes and thymocytes of rats with brain tumors chronologically from the early stage to the late stage, in order to clarify how much LAK activity would be developed at each stage. Simultaneously the natural killer (NK) activity in splenocytes, as one aspect of the host immunocompetence, was also determined. The splenic NK activity was significantly depressed in rats with brain tumors during the 2nd and 3rd weeks after tumor transplantation, as compared with normal controls. On the other hand, the splenocytes incubated with interleukin-2 showed the same killer activity in rats with brain tumors as in normal rats at all times. The LAK activity in thymocytes from rats with brain tumors was significantly higher than that of controls in the 1st and 2nd weeks and became equal to that of the controls during the 3rd week. The killer activity after incubation with interleukin-2 in thymocytes was superior to that in splenocytes throughout the experiment in both tumor-bearing rats and controls, which suggested that the precursor of LAK cells was not NK cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH (1989) Intratumoral LAK cell and interleukin-2 therapy of human glioma. J Neurosurg 70: 175
Bardos P, Degenne D, Lebranchu Y, Biziere K, Renoux G (1981) Neocortical lateralization of NK activity in mice. Scand J Immunol 13: 609
Bosnes V, Hirschberg H (1988) Comparison of in vivo glioma cell cytotoxicity of LAK cells from glioma patients and healthy subjects. J Neurosurg 69: 234
Braun DP, Penn RD, Harris JE (1984) Regulation of natural killer cell function by glass-adherent cells in patients with primary intracranial malignancies. Neurosurgery 15: 29
Brooks WH, Netsky MG, Normansell DE, Horwitz DA (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors. J Exp Med 136: 1631
Cross RJ, Markesbery WR, Brooks WH, Roszman TL (1984) Hypothalamic immune interactions: neuromodulation of natural killer activity by lesioning of the anterior hypothalamus. Immunology 51: 399
Imaya H, Matsuura H, Kudo M, Nakazawa S (1988) Induction of lymphokine-activated killer cells from rat thymocytes using recombinant human interleukin-2. Cancer Immunol Immunother 27: 13
Imaya H, Matsuura H, Kudo M, Nakazawa S (1988) Suppression of splenic natural killer cell activity in rats with brain tumors. Neurosurgery 23: 23
Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA (1986) In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg 64: 114
Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA (1986) Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg 64: 743
Jacobs SK, Melin G, Holcomb B, Parham CW, Kornblith PL, Grimm EA (1986) Lymphokine activated killer (LAK) cell-mediated lysis of murine glioma: trypsin-chymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells. Brain Res 372: 386
Kuribayashi K, Gillis S, Kern DE, Henney CS (1981) Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. J Immunol 126: 2321
Männel DN, Mizel SB, Diamantstein T, Falk W (1985) Induction of interleukin-2 responsiveness in thymocytes by synergistic action of interleukin-1 and interleukin-2. J Immunol 134: 3108
Matsuura H, Nakazawa S (1985) Prognostic significance of serum α1-acid glycoprotein in patients with glioblastoma multiforme: a preliminary communication. J Neurol Neurosurg Psychiatry 48: 835
McCutcheon IE, Baranco RA, Katz DA, Saris SC (1990) Adoptive immunotherapy of interacerebral metastases in mice. J Neurosurg 72: 102
Shimizu K, Okamoto Y, Miyao Y, Yamada M, Ushio Y, Hayakawa T, Ikeda H, Mogami H (1987) Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2. J Neurosorg 66: 519
Takai N, Tanaka R, Yoshida S, Hara N, Saito T (1988) In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells. Cancer Res 48: 2047
Yoshida S, Takai N, Tanaka R (1987) Functional analysis of interleukin-2 in immune surveillance against brain tumors. Neurosurgery 21: 627
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matsuura, H., Imaya, H. Comparison of lymphokine-activated killer activities between thymocytes and splenocytes in rats with brain tumors. Cancer Immunol Immunother 33, 50–53 (1991). https://doi.org/10.1007/BF01742528
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01742528